Rhein Biotech: Revenue expected to grow by 15.36% year-over-year in 2025, with multiple efforts to strengthen the advantages of the entire industry chain

On March 31, Rhein Biotech disclosed its 2025 annual report. During the reporting period, the company focused on its core natural health products business, with steady expansion of its operating scale. For the full year, it achieved operating revenue of 2.04B yuan, up 15.36% year over year; net cash flow from operating activities was 160 million yuan, up slightly by 0.31% year over year.

Core natural business sees both volume and price rise; natural sweeteners drive growth

According to materials, the company’s main business is research and production of natural health functional ingredients. Its products include monk fruit extract, stevia extract, tea extract, and others. Downstream applications include food and beverages, health supplements, beauty and skincare, animal feed, and pet nutrition. In 2025, the natural sweeteners business achieved revenue of 1.18B yuan, up 24.19%; the tea extract business achieved revenue of 214 million yuan, up 17.50%; and the other extract business achieved revenue of 570 million yuan.

In addition, the company completed 112 customer formulation debugging projects throughout the year, rolled out 189 products and compounding formulas, and generated 115 million yuan in formulation sales revenue, with high-value businesses advancing steadily.

Breakthroughs in synthetic biology; global capacity planning implemented

The announcement mentions that during the reporting period, the company’s technological innovation and capacity upgrade delivered significant results. On the technology innovation front, the transformation of synthetic biology achievements accelerated. The synthetic biology stevia glycoside RebM2 product passed the U.S. FDA GRAS certification, and approval for a new variety of domestic food additive is underway; products such as levorotatory β-galactomannan achieved commercialization and rollout. The company already holds 192 patents for inventions and utility models, and its technical barriers have been continuously strengthened.

On the capacity upgrade front, the factory in Indiana, the U.S. was converted into an integrated extraction plant, forming a dual supply-chain layout of China + the U.S., closer to North America’s core markets. This shortens delivery cycles and enhances global supply stability and competitiveness.

On the raw material supply front, the company adopts a company + cooperatives + farmers model to ensure stable supply of core raw materials such as monk fruit and stevia, strengthening its advantages across the entire industry chain.

The announcement shows that during the reporting period, the company reached a strategic cooperation with DeFu Capital. It plans to bring in high-quality resources from the healthy and wellness industry through methods such as transferring control rights and purchasing assets by issuing shares, to improve the full-industry-chain layout of “raw materials—R&D—formulations—applications.”

As the first listed company in China’s plant extraction industry, Rhein Biotech holds multiple authoritative qualification certifications such as “National-level Green Factory,” “National-level specialized and innovative ‘little giant’ enterprise,” and “National Key Leading Enterprise for Agricultural Industrialization.” Relying on its three core advantages—full-industry-chain layout, technological innovation, and global influence—the company has established a leading position in the global plant extraction field. In the future, the company will continue to uphold the operating philosophy of “green technology, healthy future,” leverage its strong advantages integrating production, sales, and research, continue to implement the strategy of developing major single products, and work to become the most trustworthy provider of natural health product services worldwide. (Wang Luò)

【Source: China Securities Journal · CNR.com】